Premium
A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community‐dwelling Mexican Americans and non‐Hispanic Whites: A method for increasing representation of diverse populations in clinical research
Author(s) -
O'Bryant Sid E.,
Zhang Fan,
Petersen Melissa,
Hall James R.,
Johnson Leigh A.,
Yaffe Kristine,
Mason David,
Braskie Meredith,
Barber Robert A.,
Rissman Robert A.,
Mapstone Mark,
Mielke Michelle M.,
Toga Arthur W.
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12382
Subject(s) - dementia , ethnic group , neuropsychology , medicine , disease , cognitive impairment , gerontology , cognition , clinical psychology , cognitive decline , psychology , psychiatry , sociology , anthropology
Representation of Mexican Americans in Alzheimer's disease (AD) clinical research has been extremely poor. Methods Data were examined from the ongoing community‐based, multi‐ethnic Health & Aging Brain among Latino Elders (HABLE) study. Participants underwent functional exams, clinical labs, neuropsychological testing, and 3T magnetic resonance imaging of the brain. Fasting proteomic markers were examined for predicting mild cognitive impairment (MCI) and AD using support vector machine models. Results Data were examined from n = 1649 participants (Mexican American n = 866; non‐Hispanic White n = 783). Proteomic profiles were highly accurate in detecting MCI (area under the curve [AUC] = 0.91) and dementia (AUC = 0.95). The proteomic profiles varied significantly between ethnic groups and disease state. Negative predictive value was excellent for ruling out MCI and dementia across ethnic groups. Discussion A blood‐based screening tool can serve as a method for increasing access to state‐of‐the‐art AD clinical research by bridging between community‐based and clinic‐based settings.